Related Experiment Videos

[Effect of chronic antiplatelet treatment on platelet activating factor-induced platelet activity in stroke]

E Han1, R Joseph, S Grunfeld

  • 1Dept. of Neurology Affiliated Hospital, Shandong Medical University.

Zhonghua Shen Jing Jing Shen Ke Za Zhi = Chinese Journal of Neurology and Psychiatry
|February 1, 1991
PubMed

Insights

Chronic antiplatelet therapy did not prevent platelet activation in stroke patients. Platelet-activating factor (PAF) still triggered aggregation and calcium release, suggesting new treatments are needed.

Area of Science:

  • Cardiovascular Medicine
  • Neuroscience
  • Hematology

Background:

  • Platelet activation plays a critical role in acute ischemic stroke pathogenesis.
  • Antiplatelet therapies are standard treatments, but their efficacy in suppressing all platelet activation pathways is not fully understood.

Purpose of the Study:

  • To investigate the effectiveness of chronic antiplatelet treatment in inhibiting platelet-activating factor (PAF)-induced platelet responses in acute ischemic stroke patients.

Main Methods:

  • Studied 20 patients with acute ischemic stroke undergoing chronic antiplatelet therapy.
  • Assessed PAF-induced platelet aggregation, adenosine triphosphate (ATP) release, and cytoplasmic ionized calcium levels.

Main Results:

  • Chronic antiplatelet treatment did not significantly suppress PAF-induced platelet aggregation.
  • PAF-induced ATP release and cytoplasmic ionized calcium elevation remained unaffected by the treatment.

Conclusions:

  • Current chronic antiplatelet regimens may be insufficient to block PAF-mediated platelet activation in stroke.
  • Selective PAF antagonists represent a potential therapeutic strategy for improving stroke treatment by targeting PAF pathways.

Related Concept Videos